Cibus (CBUS) Profit After Tax (2016 - 2026)
Cibus (CBUS) posted Profit After Tax of -$31.9 million for Q4 2025, down 35.71% sequentially from -$23.5 million in Q3 2025, and down 678.65% YoY from $5.5 million in Q4 2024.
Cibus (CBUS) Profit After Tax (2016 - 2026) Analysis & Trends
Cibus has reported Profit After Tax for 10 years, with the latest figure at -$31.9 million in Q4 2025.
- Quarterly Profit After Tax fell 678.65% year-over-year to -$31.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$131.4 million (up 41.93% YoY) and the FY2025 annual result came in at -$132.2 million, up 47.41% from the prior year.
- Profit After Tax eased to -$31.9 million in Q4 2025 per CBUS's latest filing, from -$23.5 million in the prior quarter.
- Over five years, Profit After Tax peaked at $5.5 million in Q4 2024 and troughed at -$287.1 million in Q4 2023.
- A 5-year average of -$37.6 million and a median of -$15.3 million in 2021 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax plunged 10020.76% in 2023, then surged 101.92% in 2024.
- Over 5 years, Profit After Tax stood at -$7.1 million in 2021, then soared by 59.8% to -$2.8 million in 2022, then tumbled by 10020.76% to -$287.1 million in 2023, then surged by 101.92% to $5.5 million in 2024, then tumbled by 678.65% to -$31.9 million in 2025.
- According to Business Quant data, Profit After Tax over the past three periods registered -$31.9 million, -$23.5 million, and -$26.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -16.62 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | Cibus | 131.25 Mn | 110.82 Mn | - | -22.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.15 Mn |
| Dec 31, 2025 | -31.95 Mn |
| Sep 30, 2025 | -23.54 Mn |
| Jun 30, 2025 | -26.56 Mn |
| Mar 31, 2025 | -49.39 Mn |
| Dec 31, 2024 | 5.52 Mn |
| Sep 30, 2024 | -179.97 Mn |
| Jun 30, 2024 | -28.48 Mn |
| Mar 31, 2024 | -23.44 Mn |
| Dec 31, 2023 | -287.13 Mn |
| Sep 30, 2023 | -34.53 Mn |
| Jun 30, 2023 | -20.51 Mn |
| Mar 31, 2023 | -5.39 Mn |
| Dec 31, 2022 | -2.84 Mn |
| Sep 30, 2022 | -5.95 Mn |
| Jun 30, 2022 | -2.49 Mn |
| Mar 31, 2022 | -5.62 Mn |
| Dec 31, 2021 | -7.06 Mn |
| Sep 30, 2021 | -7.31 Mn |
| Jun 30, 2021 | -4.81 Mn |